2015
Recursive partitioning analysis of prognostic factors in post‐transplant lymphoproliferative disorders (PTLD): a 120 case single institution series
Montanari F, Radeski D, Seshan V, Alobeid B, Bhagat G, O'Connor OA. Recursive partitioning analysis of prognostic factors in post‐transplant lymphoproliferative disorders (PTLD): a 120 case single institution series. British Journal Of Haematology 2015, 171: 491-500. PMID: 26250758, DOI: 10.1111/bjh.13621.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedChildChild, PreschoolCombined Modality TherapyEpstein-Barr Virus InfectionsFemaleHumansImmunosuppressive AgentsInfantLymphoproliferative DisordersMaleMiddle AgedMultivariate AnalysisOrgan TransplantationPostoperative ComplicationsPrognosisRisk AssessmentRituximabSeverity of Illness IndexYoung AdultConceptsPost-transplant lymphoproliferative disorderECOG scoreElderly patientsPediatric patientsLymphoproliferative disordersEastern Cooperative Oncology Group scoreECOG score 0Setting of immunosuppressionDecade of diagnosisNew prognostic scoreSingle-institution seriesHigh-risk groupAdult patientsOverall survivalPrognostic factorsPrognostic scoreInstitution seriesSingle institutionScore 0Tissue allograftsPatientsLarge seriesRisk categoriesHeterogeneous groupRecursive partitioning model
2010
Post Transplant Lymphoproliferative Disorders: Prognostic Features and Rituximab Impact In a 120 Case Single Institution Series
Montanari F, Bhagat G, Seshan V, Clark-Garvey S, Zain J, Diefenbach C, McCormick E, Conroy M, Crook M, Alobeid B, O'Connor O. Post Transplant Lymphoproliferative Disorders: Prognostic Features and Rituximab Impact In a 120 Case Single Institution Series. Blood 2010, 116: 4151. DOI: 10.1182/blood.v116.21.4151.4151.Peer-Reviewed Original ResearchPost-transplant lymphoproliferative disorderECOG score 0Epstein-Barr virusEpstein-Barr virus statusECOG scoreP-PTLDAdult patientsPediatric patientsScore 0Immunosuppression taperingM-PTLDRituximab groupMedian OSEarly lesionsLymphoproliferative disordersAdvanced stage III or IVPTLD subtypesIntermediate-low-risk groupSpectrum of lymphoproliferative disordersMedian OS of patientsIntermediate-high risk groupHematopoietic stem cell transplantationWorld Health Organization classification systemStage III or IVPopulation of adult patients